Based on the good results achieved in advanced HER2-amplified breast cancer patients, we also tested pertuzumab, a humanized monoclonal HER2-targeted antibody that binds to a different epitope on the HER2 receptor than trastuzumab. Here, ERBB2 is linked to breast cancer.